About UNITED LAB Company

Federal Pharmaceutical (stock code 03933.HK) was founded in Hong Kong in 1990. Currently, it has six production entities: Federal Pharmaceutical Co., Ltd. (Hong Kong), Zhuhai Federal Pharmaceutical Co., Ltd., Zhongshan Branch, Guangdong Kaiping Jinyi Capsule Co., Ltd., Federal Pharmaceutical (Inner Mongolia) Co., Ltd., and Inner Mongolia Federal Animal Protection Pharmaceutical Co., Ltd., a professional chemical and biological products research and development center. The products cover pharmaceutical intermediates, raw materials and formulations, with a total of more than 14,000 employees. Pharmaceutical Group. All of Federal Pharmaceutical's workshops have passed the new GMP certification in China, and several products have successively obtained EU GMP certification and US FDA certification. With advanced enzymatic production technology, Federal Pharmaceuticals became the first domestic company to obtain the EU CEP certificate for enzymatic amoxicillin, and many other scientific and technological achievements have obtained national patents. Federal Pharmaceuticals currently has 11 series of over 60 varieties of pharmaceutical products with more than 110 product specifications. Among them, Bangdeqing has obtained a national invention patent certificate and is the first domestic counterfeit product to treat moderate to severe Alzheimer's dementia. Antibiotic products such as amoxen, tazoxine, and abixen have been selling well for many years. Their excellent curative effects and quality have been highly trusted and praised by users. The Group continues to advance consistency evaluation work. Currently, several products such as federal amoxin capsules (0.25g), federal safoxin tablets (0.25g), and Bondeqin Memantine hydrochloride tablets (10mg) have passed the consistent evaluation of generic drug quality and efficacy, showing that they are consistent with the original drug in terms of quality and efficacy, and can be replaced with the original drug clinically. Federal Pharmaceuticals has been committed to biopharmaceutical research for more than 10 years, and has invested heavily to establish large-scale production bases for human insulin and analogues in Zhuhai and Zhongshan, integrating production and research in the field of diabetes biopharmaceuticals. Currently, the products on the market include the insulin injection “USLIN”, the glycine insulin injection “Federation Euleling USLEN”, and the Mendon insulin injection federal Ublin series products. USLIN and Ubeling Ublin Ublin series products use Pichia yeast expression technology, which has the advantages of high purity, good safety, and affordability. The glycine insulin injection “Federal Eulerin USLEN” uses advanced purification technology, and the product quality conforms to US Pharmacopeia standards. Federal Pharmaceuticals is the first domestic company to have both second-generation and third-generation insulin production capabilities. Federal Pharmaceuticals has advanced production equipment and sufficient production capacity. The current annual production capacity is 1.8 billion capsules, 1 billion tablets, 0.134 billion bags of granules, 86 million bags of suspensions, 20 million bottles of oral liquid, 0.117 billion bottles of powder injections, 37.8 million bottles of ointment, 28 million bottles of freeze-dried powder needles, 24 million for eye drops, and 0.3 billion for insulin preparations. Federal Pharmaceuticals insists on putting equal emphasis on development and environmental protection, and follows the path of sustainable development. It has successively invested nearly 2 billion yuan in environmental protection management, introduced advanced international technology and equipment, and worked hard to build green productivity, and won a series of honorary titles such as “Excellent Innovative Enterprise in Guangdong Province” and “Environmental Social Responsibility Enterprise”. Since 1998, Federal Pharmaceuticals has completed more than 30 foreign donation projects in the fields of education, disaster relief, and social welfare, with a donation amount of nearly 100 million yuan, and has organized many times for employees to participate in public welfare activities such as unpaid blood donation, social volunteering, and social charity, reflecting its responsibility and mission as a modern enterprise. As always, Federal Pharmaceutical adheres to the promise of “making life more valuable”, and is committed to promoting the development of China's medical and health services and providing more high-quality and efficient pharmaceutical products to the community.